Table 3 Concurrent therapy and prognostic factors
| Â | MGMT (methylated, not methylated) | IDH (mutated, not mutated) | Age (years) (59 or less, > 60) | KPS (90 or 100, 70 or 80) |
|---|---|---|---|---|
No vaccine (n = 3) | 1 vs 2 | 0 vs 3 | 1 vs 2 | 2 vs 1 |
2 or 3 vaccinations, no concurrent therapy (n = 8) | 3 vs 5 | 1 vs 7 | 4 vs 4 | 1 vs 7 |
Concurrent TMZ alone (n = 29) | 8 vs 21 | 4 vs 25 | 18 vs 11 | 17 vs 12 |
Concurrent TMZ + bevacizumab (n = 11) | 3 vs 8 | 2 vs 9 | 7 vs 4 | 6 vs 5 |
Concurrent TMZ + TTF (n = 6) | 3 vs 3 | 0 vs 6 | 2 vs 4 | 3 vs 3 |
Concurrent TMZ + TTF + bevacizumab (n = 3) | 1 vs 2 | 0 vs 3 | 1 vs 2 | 2 vs 1 |
Total (n = 60) | 19 vs 41 | 7 vs 53 | 33 vs 27 | 31 vs 29 |